<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> is an independent risk factor for <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> and cardiovascular mortality </plain></SENT>
<SENT sid="1" pm="."><plain>However, the mechanism by which <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> contributes to <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Conceivably, <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> could be involved </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we asked whether therapy for <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> ameliorates any <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: We performed a double-blind cross-over trial of 12 patients with recently diagnosed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>They received <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> 4 mg b.i.d. for 12 weeks and nateglinide 60 mg b.i.d. for the same number of weeks in random order </plain></SENT>
<SENT sid="6" pm="."><plain>To assess the degree of <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, we used venous occlusion plethysmography </plain></SENT>
<SENT sid="7" pm="."><plain>We studied vasodilation in response to <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> (<z:chebi fb="0" ids="15355">ACh</z:chebi>) with and without exogenous insulin </plain></SENT>
<SENT sid="8" pm="."><plain>The agents were infused into the brachial artery </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, we determined <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> by euglycemic clamp </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: Glycemic control was comparable under <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and nateglinide </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> ameliorated <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> by 60% compared with nateglinide </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="15355">ACh</z:chebi> response was significantly increased after <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> treatment (maximum forearm blood flow 12.8 +/- 1.3 vs. 8.8 +/- 1.3 ml/100 ml after <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and nateglinide, respectively; P &lt; 0.05) but did not attain the level of healthy control subjects (14.0 +/- 0.7 ml/100 ml) </plain></SENT>
<SENT sid="13" pm="."><plain>Coinfusion of exogenous <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">insulin increased</z:e> <z:chebi fb="0" ids="15355">ACh</z:chebi> response further in the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="0" ids="28229">N-monomethyl-L-arginine</z:chebi>-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (<z:chebi fb="0" ids="28229">L-NMMA</z:chebi>), an <z:chebi fb="68" ids="48706">antagonist</z:chebi> of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase, largely prevented the <z:mp ids='MP_0005590'>increased vasodilation</z:mp> after <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, regardless of the presence or absence of insulin </plain></SENT>
<SENT sid="15" pm="."><plain>Insulin sensitivity and blood flow response were found to be correlated (P &lt; 0.01) </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> is a major contributor toward <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="17" pm="."><plain>Both <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> are amenable to treatment by <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> </plain></SENT>
</text></document>